UK markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.47-0.93 (-3.81%)
As of 02:15PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.04B
Enterprise value 2.14B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)36.38
Price/book (mrq)3.31
Enterprise value/revenue 25.88
Enterprise value/EBITDA -7.59

Trading information

Stock price history

Beta (5Y monthly) 1.90
52-week change 3-62.25%
S&P500 52-week change 3-5.12%
52-week high 379.70
52-week low 320.24
50-day moving average 328.47
200-day moving average 340.58

Share statistics

Avg vol (3-month) 3540.94k
Avg vol (10-day) 3725.15k
Shares outstanding 5122.95M
Implied shares outstanding 6N/A
Float 895.29M
% held by insiders 120.55%
% held by institutions 180.45%
Shares short (28 Apr 2022) 46.66M
Short ratio (28 Apr 2022) 415.36
Short % of float (28 Apr 2022) 48.06%
Short % of shares outstanding (28 Apr 2022) 45.42%
Shares short (prior month 30 Mar 2022) 46.74M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-351.15%

Management effectiveness

Return on assets (ttm)-12.68%
Return on equity (ttm)-28.25%

Income statement

Revenue (ttm)82.88M
Revenue per share (ttm)0.68
Quarterly revenue growth (yoy)431.90%
Gross profit (ttm)-216.69M
EBITDA -282.46M
Net income avi to common (ttm)-285.76M
Diluted EPS (ttm)-2.34
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)957.52M
Total cash per share (mrq)7.79
Total debt (mrq)62.74M
Total debt/equity (mrq)6.84
Current ratio (mrq)2.90
Book value per share (mrq)7.47

Cash flow statement

Operating cash flow (ttm)-233.26M
Levered free cash flow (ttm)180.7M